Maxim Group analyst Michael Okunewitch has maintained their bullish stance on ATAI stock, giving a Buy rating yesterday.
Michael Okunewitch has given his Buy rating due to a combination of factors including ATAI Life Sciences’ strong financial position and promising pipeline developments. The company reported an operating loss for 4Q24 and the full year, but it maintains a solid cash position with sufficient funding projected through 2027, bolstered by recent fundraising efforts.
ATAI’s pipeline includes several key programs that are progressing well, such as the Phase 2 studies for VLS-01 in treatment-resistant depression and EMP-01 in social anxiety disorder, with significant data expected in 2026. Additionally, the partnership with Beckley Psytech on BPL-003 for treatment-resistant depression is anticipated to yield important data in mid-2025. The upcoming results from RL-007 in cognitive impairment associated with schizophrenia also represent a potential catalyst. These developments, along with the strategic focus on short-acting psychedelic treatments, underpin the positive outlook for ATAI’s stock.
According to TipRanks, Okunewitch is an analyst with an average return of -20.9% and a 27.07% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Ocugen, Lineage Therap, and Mediwound.